The cancer therapeutics developer has followed up an Eli Lilly-backed first close with an extra $25m, taking the round to $82.6m.

US-based small molecule drug developer Cedilla Therapeutics expanded a series B round backed by pharmaceutical firm Eli Lilly to $82.6m yesterday with another $25m.

The oversubscribed extension included RA Capital Management, Woodline Partners, Janus Henderson Investments, Logos Capital and Third Rock Ventures, and RA Capital partner Jake Simpson will join the company’s board of directors in conjunction with the financing.

Cedilla is developing small molecule therapeutics to target hard-to-reach cancer-facilitating proteins TEAD and CDK2. It will use the funding to…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Robert Lavine

Robert Lavine is special features editor for Global Venturing.
Email LinkedIn